0001209191-20-025491.txt : 20200423 0001209191-20-025491.hdr.sgml : 20200423 20200423201928 ACCESSION NUMBER: 0001209191-20-025491 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200423 FILED AS OF DATE: 20200423 DATE AS OF CHANGE: 20200423 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Heyman Richard A. CENTRAL INDEX KEY: 0001584759 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39269 FILM NUMBER: 20812262 MAIL ADDRESS: STREET 1: 5871 OBERLIN DRIVE, SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oric Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001796280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 471787157 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 240 E. GRAND AVE. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 388-5600 MAIL ADDRESS: STREET 1: 240 E. GRAND AVE. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-04-23 0 0001796280 Oric Pharmaceuticals, Inc. ORIC 0001584759 Heyman Richard A. C/O ORIC PHARMACEUTICALS, INC. 240 E. GRAND AVE., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 12500 D Common Stock 165000 I See footnote Series A Preferred Stock Common Stock 62500 I See footnote Stock Option (right to buy) 1.60 2028-02-28 Common Stock 46928 D Stock Option (right to buy) 1.60 2028-06-28 Common Stock 18125 D The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. The Series A Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. The shares subject to the option are fully vested and immediately exercisable. The option is subject to an early exercise provision and is immediately exercisable. One fourth (1/4th) of the shares subject to the option vested on May 10, 2019, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. /s/ Dominic Piscitelli, attorney-in-fact 2020-04-23 EX-24.3_911064 2 poa.txt POA DOCUMENT POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of Oric Pharmaceuticals, Inc. (the "Company"), hereby constitutes and appoints Jacob Chacko, M.D. and Dominic Piscitelli, and each of them, as the undersigned's true and lawful attorney-in-fact to: 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain EDGAR codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC; 2. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and 3. do all acts necessary in order to file such forms with the SEC, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate. The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended). This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 23rd day of April, 2020. Signature: /s/ Richard Heyman Print Name: Richard Heyman